Collaboration Product Development Sample Clauses

Collaboration Product Development. Subject to Article 9 if the Parties Co-Promote, Warner shall be responsible for all costs of conducting Development of Collaboration Product(s) in the Territory, including, without limitation, expenses incurred in conducting clinical trials for Collaboration Products for which it retains commercialization rights thereto. In addition, Warner shall be responsible, at its sole expense, for all commercialization of such Collaboration Product(s) in the Territory so long as Warner retains rights thereto under this Agreement. During the term of this Agreement, Warner shall keep GenVec fully informed of its activities subject to this Agreement, including without limitation, the achievement of the milestones set forth in Sections 6.4 and 8.2.2 and the commercialization of the Collaboration Product(s). On or before January 31 of each year, at GenVec's request, Warner shall provide GenVec with a written report summarizing such events and activities and detailing those which have not been previously reported. When a registration package requesting approval for commercial sale of any Collaboration Product is first filed in any country within the Territory, and when approval is received therefor, Warner will immediately notify GenVec in writing.
AutoNDA by SimpleDocs
Collaboration Product Development. At the end of Collaboration Stage 1, and on a Collaboration Product-by-Collaboration Product basis, the Parties will meet, through the JRC, to discuss the further development and commercialization of such Collaboration Product. At such time, and subject to the principles set forth below in Sections 4.1.1 through 4.1.4, the Parties shall, within sixty (60) days of the end of Collaboration Stage 1 (the “Election Period”), elect to (i) negotiate and enter into a definitive co-development agreement for such Collaboration Product, (ii) negotiate and enter into a definitive license agreement where one Party (the “Developing Party”) is responsible for the development of such Collaboration Product, or (iii) seek a third party to develop such Collaboration Product.
Collaboration Product Development. Subject to Article 9 if the --------------------------------- Parties Co-Promote, Warner shall be responsible for all costs of conducting Development of Collaboration Product(s) in [*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. -28- the Territory, including, without limitation, expenses incurred in conducting clinical trials for Collaboration Products for which it retains commercialization rights thereto. In addition, Warner shall be responsible, at its sole expense, for all commercialization of such Collaboration Product(s) in the Territory so long as Warner retains rights thereto under this Agreement. During the term of this Agreement, Warner shall keep GenVec fully informed of its activities subject to this Agreement, including without limitation, the achievement of the milestones set forth in Sections 6.4 and 8.2.2 and the commercialization of the Collaboration Product(s). On or before January 31 of each year, at GenVec's request, Warner shall provide GenVec with a written report summarizing such events and activities and detailing those which have not been previously reported. When a registration package requesting approval for commercial sale of any Collaboration Product is first filed in any country within the Territory, and when approval is received therefor, Warner will immediately notify GenVec in writing.

Related to Collaboration Product Development

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Product Development Attach all requested documentation and attach additional pages as necessary. For all requirements include efforts of all Sublicensees. If not applicable, please so indicate by N/A.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

Time is Money Join Law Insider Premium to draft better contracts faster.